checkAd
    Startseite > Aktien > Arvinas > Nachrichten
    Arvinas Aktie
    32,37
     
    USD
    +2,44 %
    +0,77 USD
    Letzter Kurs 27.04.24 Nasdaq
    32,37
     
    USD
    1.500 STK
    Geldkurs 26.04.24
    32,39
     
    USD
    2.200 STK
    Briefkurs 26.04.24
    ISIN: US04335A1051 · WKN: A2N6VP · SYM: ARVN · USA

    Neueste Nachrichten

    Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
    24.04.24 · globenewswire · Arvinas
    Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
    11.04.24 · globenewswire · Arvinas
    Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
    18.03.24 · globenewswire · Arvinas
    Arvinas to Participate in Upcoming Investor Conferences
    04.03.24 · globenewswire · Arvinas
    Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    27.02.24 · globenewswire · Arvinas
    Arvinas Announces Chief Financial Officer Transition
    20.02.24 · globenewswire · Arvinas
    Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC Protein Degrader for Neurodegenerative Disease
    20.02.24 · globenewswire · Arvinas
    Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
    06.02.24 · globenewswire · Arvinas
    Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
    01.02.24 · globenewswire · Arvinas
    Arvinas Appoints Jared Freedberg as General Counsel
    16.01.24 · globenewswire · Arvinas
    Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
    28.11.23 · globenewswire · Arvinas
    Arvinas Announces Oversubscribed $350 Million Private Placement
    27.11.23 · globenewswire · Arvinas